ArticleCureus2025
Rituximab-Induced Serum Sickness in a Seven-Year-Old Child With Nephrotic Syndrome.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Clinical characteristics, diagnosis, treatment, and prognosis of rituximab-induced serum sickness: a retrospective analysis of 39 reported cases.Frontiers in immunology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this article is to report an unusual side effect of rituximab in a child. We describe a seven-year-old boy with steroid-dependent nephrotic syndrome who presented with fever and severe polyarthralgia after his first dose of rituximab. The onset of symptoms 13 days after rituximab administration, the self-limited evolution of symptoms, the exclusion of other causes, and the presence of similar reports led to the diagnosis of rituximab-induced serum sickness as a possible adverse reaction. The benefits of rituximab have been reported in steroid-dependent nephrotic syndrome with frequent relapses. However, most of the available evidence derives from studies in adults. The communication and analysis of pharmacovigilance data, both from spontaneous reporting and active surveillance, are important for defining the role of new drugs in treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.